ProCE Banner Activity

Phase I/II Trial of Mobocertinib in EGFR ex20ins+ Advanced NSCLC: Analysis of Patient Cohort With Disease Control on Prior EGFR TKI Therapy

Slideset Download
Conference Coverage
In this analysis of a dose-expansion cohort from an ongoing phase I/II trial, mobocertinib was associated with clinical activity and manageable safety in patients with EGFR ex20ins–positive advanced NSCLC with disease progression after responding to or achieving stable disease on prior EGFR TKI therapy.

Released: September 23, 2021

Expiration: September 22, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bayer Healthcare Pharma

Daiichi Sankyo, Inc.

Janssen administered by Scientific Affairs

Janssen Pharmaceutica NV

Millennium Pharmaceuticals Inc Subsidary of Takeda

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme